The estimated Net Worth of William Mariner Greenman is at least 10.1 百万$ dollars as of 12 March 2024. Mr. Greenman owns over 125,926 units of Cerus stock worth over 6,521,626$ and over the last 18 years he sold CERS stock worth over 348,839$. In addition, he makes 3,270,180$ as President、 Chief Executive Officer、 Director at Cerus.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Greenman CERS stock SEC Form 4 insiders trading
William has made over 26 trades of the Cerus stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 125,926 units of CERS stock worth 256,889$ on 12 March 2024.
The largest trade he's ever made was exercising 550,000 units of Cerus stock on 16 April 2021 worth over 1,485,000$. On average, William trades about 45,403 units every 76 days since 2006. As of 12 March 2024 he still owns at least 3,181,281 units of Cerus stock.
You can see the complete history of Mr. Greenman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Greenman biography
William M. Greenman serves as President, Chief Executive Officer, Director of the Company. Mr. Greenman served as our Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named our Chief Business Officer in April 2010. Mr. Greenman served as our President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006, Mr. Greenman served as our Vice President, Business Development after returning to Cerus after a brief time in the venture capital business. Prior to joining us in 1995 as Director of Business Development, Mr. Greenman worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman has served on the board of directors of Aduro Biotech, Inc., a public clinical-stage immunotherapy company, since June 2010. Mr. Greenman holds a B.A.S. in economics and biological sciences from Stanford University.
What is the salary of William Greenman?
As the President、 Chief Executive Officer、 Director of Cerus, the total compensation of William Greenman at Cerus is 3,270,180$. There are no executives at Cerus getting paid more.
How old is William Greenman?
William Greenman is 53, he's been the President、 Chief Executive Officer、 Director of Cerus since 2011. There are 10 older and 3 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
What's William Greenman's mailing address?
William's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Insiders trading at Cerus
Over the last 21 years, insiders at Cerus have traded over 5,083,598$ worth of Cerus stock and bought 1,382,745 units worth 4,903,526$ . The most active insiders traders include William Mariner Greenman、Laurence M Corash、Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of 90,805$. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth 178,539$.
What does Cerus do?
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
What does Cerus's logo look like?
Complete history of Mr. Greenman stock trades at Aduro BioTech、Cerus
Cerus executives and stock owners
Cerus executives and other stock owners filed with the SEC include:
-
William Greenman,
President, Chief Executive Officer, Director -
Vivek Jayaraman,
Chief Operating Officer, Chief Commercial Officer -
Laurence Corash,
Chief Scientific Officer -
Richard Benjamin,
Chief Medical Officer -
Kevin Green,
Chief Financial Officer, Vice President - Finance -
Carol Moore,
Senior Vice President - Regulatory Affairs, Quality and Clinical -
Chrystal Menard,
Chief Legal Officer and General Counsel -
Jami Nachtsheim,
Independent Director -
Daniel Swisher,
Independent Chairman of the Board -
Timothy Anderson,
Independent Director -
Frank Witney,
Independent Director -
Gail Schulze,
Independent Director -
Eric Bjerkholt,
Independent Director -
Timothy Moore,
Independent Director -
Tim Lee,
Investor Relations Director -
William J Dawson,
Chief Financial Officer -
Caspar Jan Hogeboom,
Managing Director Cerus Europe -
Bruce C Cozadd,
Director -
David N Cook,
Vice President, R & D -
Chrystal Jensen,
Chief Legal Officer -
Stephen T Isaacs,
Chief Executive Officer -
Gregory W Schafer,
Chief Financial Officer -
International Inc & Subsidi...,
10% owner -
C Raymond Jr Larkin,
Director -
Bj Cassin,
Director -
Howard G Ervin,
Vice President, Legal Affairs -
Claes Glassell,
Executive Officer and Director -
William R Rohn,
Director -
Dean A. Gregory,
-
Ann Lucena,
Director -
Hua Shan,
Director